Allyx Therapeutics Inc.

[Not Yet Scheduled]
Allyx Therapeutics is a clinical stage biotechnology company based in New Haven, CT. We aim to deliver a first-in-class oral drug which preserves synapses and restores neuronal network function as a disease-modifying approach for treating neurodegenerative diseases. Our lead candidate, ALX-001, is an orally bioavailable small molecule drug which acts as a silent allosteric modulator of mGluR5 to selectively block Cellular Prion Protein initiated synaptic dysfunction. ALX-001 reverses cognitive impairment and rescues synapse loss in multiple aged transgenic mouse models of Alzheimer’s disease (AD). The Phase 1 clinical safety studies of ALX-001 are ongoing.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Connecticut
Company HQ Country:
United States
Year Founded:
2018
Main Therapeutic Focus:
Lead Product in Development:
ALX-001
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
Co-Founder, President & COO
Allyx Therapeutics